Under the Agreement, Abbott will share insights from recent HeartMate 3™ trials and will support Cadrenal with: trial design, site identification, trial awareness, and HeartMate 3™ expertise.
Two-thirds of the participants will be randomly assigned to receive the BrioVAD, while one-third will receive Abbott’s HeartMate 3, which is the only device regularly offered to patients as a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback